Chicago, IL (PRWEB) May 02, 2013
The medication resource center DrugRisks.com is announcing new information on the site for patients taking the blood thinner Pradaxa. A federal judge has ordered drug maker Boehringer Ingelheim to disclose employee reviews and bonuses related to the blood thinner Pradaxa****.
DrugRisks was created to improve the safety of patients taking popular prescription drugs by providing the latest warnings, recalls, studies and legal news. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.
Drug safety experts disagree over whether the blood thinner Pradaxa has higher risks of internal bleeding than traditional anticoagulants. The FDA has stated the drug is as safe as warfarin*.
However, the Institute for Safe Medication Practices recently ranked blood thinners like Pradaxa among the most dangerous drugs available and warned that Pradaxa bleeding is nearly 5 times as likely to result in death than bleeding from warfarin**.
DrugRisks has also added a study from the University of Illinois at Chicago which showed the data used by the FDA may be flawed, and the risk for Pradaxa bleeding may be higher than previously thought***.
Due to the number of patients who have filed a Pradaxa lawsuit alleging the drug caused internal bleeding, cases have been consolidated to a special federal court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Now, DrugRisks has learned that Judge David Herndon, who presides over the cases, has ordered the maker of Pradaxa to produce employee performance reviews or bonuses related to the design, approval, launch, marketing, sale, regulation, or safety of the drug****.
Anyone affected by internal bleeding after taking Pradaxa is encouraged to speak with a lawyer about their legal options. Due to the specialized nature of federal drug injury cases, DrugRisks only recommends lawyers who have already handled Pradaxa lawsuits.
*FDA, 11/2/12; fda.gov/Drugs/DrugSafety/ucm326580.htm
**Instutute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
***New England Journal of Medicine, 4/4/13; nejm.org/doi/full/10.1056/NEJMp1302834
****U.S. District Court, Southern Dist. Illinois; ilsd.uscourts.gov/opinions/ilsd_live.3.12.md.2385.2339317.0.pdf#search="pradaxa"